Close Menu

NEW YORK – Molecular diagnostics company Biocartis reported on Thursday that it saw an expansion of its installed instruments base in the third quarter, with the US market representing 40 percent of new Idylla instrument placements.

The company also reported a 27 percent year-over-year increase in commercial cartridge volumes, predominantly driven by Europe and rest-of-world markets, and said the development of its liquid biopsy Idylla ctEGFR Mutation Assay during Q3 resulted in the test's launch on Oct. 25.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.

Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research. 

Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.

In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.